ISRCTN81726461进行中（未招募）1 期
Phase 1 trial: T4 immunotherapy of head and neck cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 25
研究概览
简要总结
2023 Interim results article in https://pubmed.ncbi.nlm.nih.gov/37321663/ (added 12/12/2023)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Histologically and/ or cytologically confirmed SCCHN
- •2. 18 years or older
- •3. Locally advanced and/ or recurrent head and neck cancer with or without metastatic disease (excluding brain metastases) for whom no standard therapy remains or is suitable
- •4. Regarding previous treatment, patients may have received prior systemic therapy, including platinum chemotherapy, at least one month earlier. In the presence of metastatic disease, recent short-course palliative radiotherapy to non-target site(s) is allowed
- •5. Those who refuse palliative treatment may be eligible for participation. However, their reasons for not opting for palliative treatment must be explored thoroughly
- •6. At least one loco-regional target lesion measurable by RECIST v1.1 criteria on CT or MRI scanning within four weeks of enrolment, and amenable to intra-tumoral injection
- •7. Eastern Co-operative Oncology Performance Status of 0-2
- •8. Normal cardiac function as assessed by electrocardiography and either echocardiography (ECHO), or multi-gated aquisition (MUGA) scanning. Left ventricular ejection fraction must be >50%. Assessment must take place within four weeks of enrolment
- •9. Haematology results within seven days of enrolment: neutrophilis >1.5 x 109/L, platelets >100 x 109/L, haemoglobin >9g/dl, INR <1.5
- •10. Biochemistry results within seven days of enrolment:
- •10.1. Serum creatinine <1.5 upper limit of normal
- •10.2. Bilirubin <1.25 times normal
- •10.3. ALT/ AST <2.5 times upper limit of normal (<5 times upper limit of normal if liver metastases present)
- •11. Female patients must be postmenopausal (12 months of amenorrhea), surgically sterile or they must agree to use a physical method of contraception. Oral or injectable contraceptive agents cannot be the sole method of contraception. Women of childbearing potential (WOCB) who receive cyclophosphamide must adhere to these contraceptive requirements during the trial and until 3 months after the last dose of cyclophosphamide. Male patients, even if sterlized, must agree to use a barrier method of contraception. Male subjects must also commit to use a barrier method of contraception until at least 3 months after the end of study treatment
- •12. Written informed consent prior to registration
排除标准
- •1. The presence of or imminent occurrence of airway obstruction, unless tracheostomy in place
- •2. The presence of or imminent occurrence of tumour-mediated infiltration of major blood vessels
- •3. Positive history of HIV-1, HIV-2, HTLV-1, HTLV-2, Hepatitis B, Hepatitis C or syphilis infection.
- •4. Prior splenectomy
- •5. Clinically active autoimmune disease. Sub-clinical or quiescent autoimmune disease does not exclude from participation
- •6. Treatment in the preceding week with systemic corticosteroids (> 20mg prednisolone/ day), any systemic immunomodulatory agent, radiotherapy, chemotherapy or investigational medicinal product
- •7. Concurrent use of anticoagulant therapy is not permissible
- •8. The presence of major co-morbidity likely to impair ability to undergo trial therapy, such as recent myocardial infraction, congestive cardiac failure or uncontrolled hypertension
- •9. The presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
- •10. Cyclophosphamide allergy - Final (sixth) cohort only
- •11. Pregnancy
- •12. Prior T4 immunotherapy
研究者
相似试验
招募中
1 期
Phase I Trial: T4 Immunotherapy of Head and Neck CancerHead and Neck CancerNCT01818323King's College London30
已完成
不适用
A clinical study on the effects of ?-3 fatty acids on moderate and severe acne and gut microbiotaModerate and severe acne vulgarisSkin and Connective Tissue DiseasesAcne vulgarisISRCTN31758284Affiliated Hospital of Southwest Medical University46
已完成
4 期
Tetanus vaccine safety in patients taking anti-coagulants: can it be administered intramuscularly instead of subcutaneously, as usually recommended?Patients treated with oral anticoagulants for whom at least one dose of anti-tetanus vaccine was indicatedHaematological DisordersTetanus vaccineISRCTN69942081Department of Health of Galicia (Spain)234
已完成
1 期
Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in AdultsSARS-CoV-2 InfectionNCT06026514National Institute of Allergy and Infectious Diseases (NIAID)27
进行中（未招募）
不适用
ACTIOHN: Activity as medicine in oncology for head and neckHead and Neck CancerCancerISRCTN82505455niversity of Liverpool70